Refractory overactive bladder
Conditions
Interventions
After solving Botulinum toxin A 100 units by normal saline 10 mL, 20 sites in the detrusor muscle using injection needle, avoiding the trigone of the bladder.
Sponsors
Hokusuikai kinen Hospital Department of Urology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients has non-neurogenic overactive bladder. 2)written informed consent is required. 3)At least twice a week of urinary urge incontinence was seen after anticholinergics and/or beta3-adrenergic receptor agonists could not be continued because of adverse effects.
Exclusion criteria
Exclusion criteria: 1) The patient has apparent neurogenic diseases causing urinary tract symptoms. 2) The patient underwent treatment with botulinum toxin A. 3) The patient underwent the surgery of lower urinary tract within 1 year. 4) Postvoid residual urine is 100mL or greater. 5) The patient has apparent lower urinary tract obstruction and/or weak detrusor. 6) The patient has predominantly stress urinary incontinence. 7) The patient has active urinary tract infection, malignance and/or bladder stone. 8) The patient is pregnant or breast-feed, or have possibility of such matter within 1 year. 9) The patient is diagnosed as having myasthenia gravis, Lambert-Eaton syndromeconduct , amyotrophic lateral sclerosis. 10)The patient has disturbance of swallowing and/or respiration. 11)The patient has mental and/or cognitive disturbance to conduct the clinical trial. 12) The patient is judged as being unsuitable for the trial by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of the number of daily urinary incontinence at week 12 after treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change of the number of urinary urgency incontinence, micturition, nocturia and evaluation of adverse event. | — |
Countries
Japan
Contacts
Public ContactHirotaka Sato
Hokusuikai Kinen Hospital department of urology
Outcome results
None listed